However, PHZ-treated e-Slc29a1-/- mice developed more severe anemia relative to PHZ-treated Slc29a1f/f mice, exhibiting decreased RBCs (p < 0.05), total Hb (p < 0.001) and HCT (p < 0.05), and increased MCV and MCH (p < 0.05) (Table 1). The gene discussed is SLC29A1; the disease is anemia.